Search Results
Showing Results for refractory chronic cough
As 2024 draws to a close, we’re celebrating a fantastic year of content.
Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and ...
COUGH 1 and COUGH 2, were randomized, double-blind, placebo-controlled phase 3 trials, that investigated gefapixant for the treatment of refractory or unexplained chronic cough. It was a pleasure to speak with Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) around his analysis of ...
With limited options in the treatment paradigm for refractory or unexplained chronic cough, P2X3 receptor antagonists have shown great promise in clinical trials. We were delighted to speak to Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) to discuss ...
Chronic cough is a cough that lasts 8 weeks or longer and is not due to serious underlying conditions. It is a common problem in primary care, accounting for up to 40% of referrals to pulmonologists.1 Common causes include rhinosinusitis, cough-variant asthma, ...
Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, ...
Chronic cough, defined as a cough lasting over 8 weeks, has an estimated global prevalence of 10% and has significant detrimental physical, social and psychological consequences on individuals.1,2Â Chronic cough is a complex heterogeneous disease, in which many causative factors need to ...
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary syndrome with a prevalence of approximately seven cases per 1 million individuals.1,2 PAP affects people of all age, sex, race and socioeconomic status. Based on the largest population studies conducted in the United ...
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to ...
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of ...
BLU-5937 is a highly selective P2X3 antagonist currently being investigated for the treatment of chronic cough. touchRESPIRATORY were delighted to speak with Professor Alyn Morice (Hull York Medical School, University of Hull, Castle Hill Hospital, Yorkshire, UK) around the ...
With the advent of newer drugs targeting the biochemical pathways that lead to cough, it is increasingly important to understand the definition, pathogenesis and management of this symptom. Several specialist bodies also recognize the need for guidance in this area, ...
touchRESPIRATORY were delighted to speak with Prof. Alyn H Morice (Hull York Medical School, University of Hull, Yorkshire, UK) to discuss the phase 2 trial, investigating BLU-5937 a selective P2x3 antagonist for the treatment of refractory chronic cough. The abstract ...
touchRESPIRATORY caught up with Dr. Michael S. Blaiss (Medical College of Georgia, Augusta University, Augusta, GA, USA) to discuss his analysis of phase 3 trials of gefapixant in chronic cough. The abstract 'Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals ...
We were delighted to talk with Dr. Michael S. Blaiss (Medical College of Georgia, Augusta University, Augusta, GA, USA) to discuss chronic cough and the latest advances to look out for in 2022. The abstract 'Comparisons Of Baseline Characteristics And Treatment ...
Aspirin-exacerbated respiratory disease (AERD) is a clinical triad of asthma, nasal polyposis and sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). These patients have severe sinopulmonary inflammation, often refractory to standard treatments.1Â However, significant advances in the management of ...
TouchRESPIRATORY got the opportunity to catch up with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to learn more about the unmet needs in chronic cough and recent clinical advances. Questions What are the ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
